Julia M. Assini
London, ON N6A5B7, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Cytosine base editing of LPA in transgenic mice averts large deletions.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: September 10, 2025
The complex pro-atherosclerotic role of lipoprotein(a): a multiplicity of cellular targets.
Journal: Current opinion in lipidology
Published: August 01, 2025
Lipoprotein(a) prolongs ex vivo plasma clot lysis times through effects on clot formation rate and fibrin structure.
Journal: Journal of thrombosis and haemostasis : JTH
Published: January 09, 2025
High levels of lipoprotein(a) in transgenic mice exacerbate atherosclerosis and promote vulnerable plaque features in a sex-specific manner.
Journal: Atherosclerosis
Published: February 28, 2023
Lipoprotein(a) induces caspase-1 activation and IL-1 signaling in human macrophages.
Journal: Frontiers in cardiovascular medicine
Published: December 22, 2022
LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: A proof-of-concept study.
Journal: Molecular therapy. Methods & clinical development
Published: May 25, 2022
Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21.
Journal: Endocrinology
Published: March 17, 2015
Gene therapy for hypercholesterolemia: sweet dreams and flying machines.
Journal: Circulation research
Published: August 30, 2014
Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr⁻/⁻ mice.
Journal: Journal of lipid research
Published: December 28, 2012
Citrus flavonoids and lipid metabolism.
Journal: Current opinion in lipidology
Published: December 21, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026